Brivaracetam (Briviact®)

Assessment Status Rapid Review complete
Drug Brivaracetam
Brand Briviact®
Indication As adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Assessment Process
Rapid review commissioned 15/02/2016
Rapid review completed 22/03/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations.